Order Article Reprints

Delbart W, Marin G, Stamatopoulos B, de Wind R, Sirtaine N, Demetter P, Vercruyssen M, Woff E, Karfis I, Ghanem GE, et al. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE. Cancers. 2023; 15(8):2332. https://doi.org/10.3390/cancers15082332

Delbart, Wendy, Gwennaëlle Marin, Basile Stamatopoulos, Roland de Wind, Nicolas Sirtaine, Pieter Demetter, Marie Vercruyssen, Erwin Woff, Ioannis Karfis, Ghanem E. Ghanem, and et al. 2023. "Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE" Cancers 15, no. 8: 2332. https://doi.org/10.3390/cancers15082332

Delbart, W., Marin, G., Stamatopoulos, B., de Wind, R., Sirtaine, N., Demetter, P., Vercruyssen, M., Woff, E., Karfis, I., Ghanem, G. E., Flamen, P., & Wimana, Z. (2023). Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE. Cancers, 15(8), 2332. https://doi.org/10.3390/cancers15082332